Targeting tumor immune checkpoints, such as programmed cell death protein 1 ligand (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), holds great promise for oncology treatment, particularly in combating glioma immune evasion [10]. Here, CTLA4 is linked to neoplasm.